CliffBio
biologic

Abrysvo

Respiratory Syncytial Virus Vaccine

Loss of exclusivityMay 2035projected — 12-year biologic exclusivity estimate
CompanyPfizer →See this company's full patent-cliff portfolio

Drug detail

Brand nameAbrysvo
Active ingredientRespiratory Syncytial Virus Vaccine
Strength120UG
Dosage formInjection
RouteIntramuscular
ModalityBiologic
FDA approvalMay 2023
Marketing statusRx

More from Pfizer

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.